Regeneron's Dupixent shows promise as COPD treatment

CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results. For access to live and exclusive video from CNBC subscribe to CNBC PRO: cnb.cx/2NGeIvi
» Subscribe to CNBC TV: cnb.cx/Subscri...
» Subscribe to CNBC: cnb.cx/Subscri...
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: www.cnbc.com/
Follow CNBC on LinkedIn: cnb.cx/LinkedI...
Follow CNBC News on Facebook: cnb.cx/LikeCNBC
Follow CNBC News on Twitter: cnb.cx/FollowCNBC
Follow CNBC News on Instagram: cnb.cx/Instagr...
www.cnbc.com/s...
#CNBC
#CNBCTV

[@barbiekat6352]

What does he mean by “Type 2 inflammation”?🤷🏻‍♀️

[@bloodshred6007]

I'm pretty sure it means stage 2 COPD.

[@PRC1020]

What is Type 2 Inflammation? Everyone has something called a type 2 immune response. 1. A type 2 immune response typically happens when your body senses certain kinds of infections or allergens and sends out specific type 2 immune cells to fight a battle against the intruders by creating inflammation

[@zaheeruddinbadar5667]

Drug Name please

[@janashawver3231]

. Duplixit​@@zaheeruddinbadar5667